ADC Therapeutics (ADCT) Free Cash Flow: 2018-2024
Historic Free Cash Flow for ADC Therapeutics (ADCT) over the last 7 years, with Dec 2024 value amounting to -$124.7 million.
- ADC Therapeutics' Free Cash Flow rose 76.88% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$121.9 million, marking a year-over-year increase of 11.86%. This contributed to the annual value of -$124.7 million for FY2024, which is 2.30% down from last year.
- As of FY2024, ADC Therapeutics' Free Cash Flow stood at -$124.7 million, which was down 2.30% from -$121.9 million recorded in FY2023.
- Over the past 5 years, ADC Therapeutics' Free Cash Flow peaked at -$121.9 million during FY2023, and registered a low of -$236.8 million during FY2021.
- In the last 3 years, ADC Therapeutics' Free Cash Flow had a median value of -$124.7 million in 2024 and averaged -$128.5 million.
- As far as peak fluctuations go, ADC Therapeutics' Free Cash Flow plummeted by 39.69% in 2021, and later spiked by 41.30% in 2022.
- Over the past 5 years, ADC Therapeutics' Free Cash Flow (Yearly) stood at -$169.5 million in 2020, then plummeted by 39.69% to -$236.8 million in 2021, then skyrocketed by 41.30% to -$139.0 million in 2022, then rose by 12.30% to -$121.9 million in 2023, then fell by 2.30% to -$124.7 million in 2024.